Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib and Methylprednisolone for Acute GVHD
NCT03701698Phase 2Terminated
- Sponsor
- Shanghai General Hospital
- Start
- Nov 2018
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Shanghai General Hospital. Primary endpoint: Overall Response Rate at 28 days. Started Nov 2018; status: terminated.
02
Drugs
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT03701698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03701698.